Norton Healthcare explains updated hormone therapy guidance for midlife women

Norton Women’s Care in Louisville is using updated guidance to help women in perimenopause and menopause decide whether to start, continue or restart treatment now. Hormone therapy is being presented less like a blanket yes-or-no decision and more like a careful fit between symptoms, timing and individual risk.

What has changed in the conversation

The biggest shift is not that hormone therapy suddenly became simple. The discussion is now more individualized than the old one-size-fits-all approach many women remember. Patients usually bring practical questions to a clinic: are my symptoms enough to treat, do I fall into a group that is likely to benefit, and how do my own risks change the picture?

The FDA held an Expert Panel on Menopause and Hormone Replacement Therapy for Women on July 17, 2025, and framed the discussion around treatments, education and comprehensive care beyond symptom management. That broader framing mirrors the way women’s health clinicians are talking now: not just about hot flashes, but about the full midlife picture, including quality of life, sleep, vaginal symptoms and the medical history that can change the balance of benefit and risk.

Who is likely to be considered

The first question is eligibility, and the answer starts with symptoms. Hormone therapies, often called HRT, are the prescription drugs used most often to treat menopause symptoms such as hot flashes and genitourinary syndrome of menopause, or GSM. GSM includes vaginal dryness after menopause, a symptom that can be easy to dismiss until it affects comfort, sex and daily life.

Timing still matters, even as the conversation has become more nuanced. A 2015 Endocrine Society review recommended that initiation of menopausal hormone therapy should generally be limited to women under 60 years of age or within 10 years after menopause onset. That is not a universal rule for every patient, but it remains a key part of how clinicians think about benefit and risk, especially when women ask whether they can start treatment later, continue treatment longer or return to it after stopping.

What hormone therapy is best at treating

The clearest evidence remains for symptom relief. The North American Menopause Society’s 2022 Hormone Therapy Position Statement called hormone therapy the most effective treatment for hot flashes and other menopause symptoms. It also said hormone therapy has been shown to prevent bone loss and fracture.

Hormone therapy remained one of the most hotly debated topics 20 years after the Women’s Health Initiative. That legacy still shapes the questions women bring into appointments now, especially if they remember earlier alarm around safety headlines and are unsure whether those warnings still apply in the same way to today’s care.

What clinicians review before prescribing

The newer approach is less about a single age cutoff and more about personal history. At Norton, that framing is especially relevant for women with complex medical backgrounds, including cardiovascular risk, migraine, breast cancer concerns or prior intolerance of medication. Those details can change whether hormone therapy is reasonable, which symptoms it should target and how closely treatment should be monitored.

The conversation is usually more detailed than a simple request for relief. A clinician is likely to ask about the pattern and severity of symptoms, the date of the final menstrual period if menopause has occurred, family history, personal history of blood clots or breast cancer, and whether previous medications were helpful or poorly tolerated. For women in perimenopause, the question is often not just whether symptoms are real, but whether they are frequent or disruptive enough to justify a prescription-based treatment plan.

Why the warning debate still matters

Hormone therapy remains under active policy and communications review. On November 10, 2025, the Society for Women’s Health Research issued a statement after an HHS press conference in which Secretary Robert F. Kennedy Jr. announced the removal of black box warnings from estrogen-based hormone replacement therapy. The Menopause Society agreed with removing the boxed warning on low-dose vaginal estrogen therapies because the warning may deter use of a treatment that helps menopausal genitourinary symptoms.

Black box warnings carry real weight in clinic conversations. When a warning is broad, it can discourage women from asking about care that may help specific symptoms, especially local vaginal treatment for GSM.

Why the guidance keeps evolving

Health systems are updating patient education as policy keeps shifting. A paper tied to the Korean Society of Menopause’s 2025 Menopausal Hormone Therapy Guidelines was received on April 3, 2025 and accepted on August 12, 2025. Guideline work is still moving internationally.